Peptides, RP1 advisory committees will test FDA’s credibility

FDA has spent the past two months signaling a return to normal: empowering career staff to make regulatory decisions, revisiting controversial decisions, and, most recently, vowing to communicate agency policy through formal guidance rather than social media posts or journal articles.

Acting FDA Commissioner Kyle Diamantas’s decision to restore the routine use of advisory committees — and to seek their input on controversial decisions made under former FDA Commissioner Marty Makary — could be a major step toward rebuilding trust in the agency...